NCT01552018View on ClinicalTrials.gov

Saxagliptin and Atherosclerosis

PHASE4CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

March 31, 2012

Primary Completion Date

February 28, 2014

Study Completion Date

February 28, 2014

Conditions
Coronary Artery DiseaseDiabetes Mellitus Type 2
Interventions
DRUG

Saxagliptin

Saxagliptin 5 mg, 1 tablet per day for 3 months

DRUG

Placebo

Placebo, 1 tablet per day for 3 months.

Trial Locations (1)

N-0424

Center for Clinical Heart Research, Dept. of Cardiology, Oslo University Hospital Ullevaal, Oslo

All Listed Sponsors
lead

Oslo University Hospital

OTHER

NCT01552018 - Saxagliptin and Atherosclerosis | Biotech Hunter | Biotech Hunter